Combining BCL-2 Family Inhibitors May Yield More Effective Senolytic Therapies

In this study, we aimed to search for synergistic selective senolytic effects. We found that combining selective MCL-1 inhibitors with non-MCL1 BCL-2 inhibitors results in marked synergistic effects with higher sensitivity of senescent compared to proliferating cells. These findings indicate that a combination of drugs targeting different BCL-2 family members can benefit for senolytic therapies.

Source: Fight Aging! - August 17, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs